McKesson Co. (NYSE:MCK) EVP Sells $114,602.92 in Stock

McKesson Co. (NYSE:MCK) EVP Leann B. Smith sold 188 shares of McKesson stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the sale, the executive vice president now directly owns 1,051 shares of the company’s stock, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

McKesson Stock Down 1.4 %

Shares of MCK stock opened at $593.82 on Friday. The business has a fifty day simple moving average of $587.26 and a 200 day simple moving average of $563.09. The company has a market cap of $74.42 billion, a P/E ratio of 27.19, a P/E/G ratio of 1.30 and a beta of 0.52. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $637.51.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. As a group, equities research analysts anticipate that McKesson Co. will post 32.69 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be issued a dividend of $0.71 per share. The ex-dividend date is Monday, March 3rd. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. McKesson’s dividend payout ratio (DPR) is presently 13.00%.

Wall Street Analyst Weigh In

MCK has been the topic of several recent research reports. Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Morgan Stanley raised their price target on shares of McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Evercore ISI boosted their price objective on shares of McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Finally, Citigroup dropped their price target on shares of McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $645.79.

Institutional Investors Weigh In On McKesson

Several hedge funds have recently modified their holdings of the company. ORG Wealth Partners LLC acquired a new stake in shares of McKesson during the third quarter valued at about $40,000. CX Institutional boosted its position in McKesson by 175.8% during the 3rd quarter. CX Institutional now owns 10,228 shares of the company’s stock worth $5,057,000 after buying an additional 6,519 shares during the period. Creative Planning grew its holdings in McKesson by 2.1% during the 3rd quarter. Creative Planning now owns 63,328 shares of the company’s stock worth $31,064,000 after acquiring an additional 1,316 shares during the last quarter. QV Investors Inc. increased its position in McKesson by 0.6% in the 3rd quarter. QV Investors Inc. now owns 3,499 shares of the company’s stock valued at $1,730,000 after acquiring an additional 20 shares during the period. Finally, Kapitalo Investimentos Ltda raised its stake in shares of McKesson by 68.5% during the third quarter. Kapitalo Investimentos Ltda now owns 723 shares of the company’s stock valued at $357,000 after acquiring an additional 294 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.